Early identification of neurobiological markers of remission. Michael Bodnar, PhD Ashok K. Malla, MD Martin Lepage, PhD

Similar documents
Source Memory is not Properly Differentiated from Object Memory in Early Schizophrenia An fmri study using virtual reality

Neurocognition and Neuroimaging Correlates of Persistent Negative Symptoms. Cindy Hovington Dr. Martin Lepage

CLINICAL EFFECTIVENESS

ORIGINAL ARTICLE. Selective Abnormal Modulation of Hippocampal Activity During Memory Formation in First-Episode Psychosis

CLINICAL EFFECTIVENESS

November 2014 MRC2.CORP.X.00004

Neuroimaging in Clinical Practice

Neuroimaging data help to clarify the nosological status of schizoaffective disorder (SAD)?

Cannabis and Psychosis: Is there an aspect of psychotic Illness that promotes cannabis use?

Biomarkers Workshop In Clinical Trials Imaging for Schizophrenia Trials

Neuroimaging of ADHD and Executive Functions

Results. NeuRA fmri March 2017

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

The Anatomical Basis of Anosognosia (Lack of Awareness of Illness)

Theory of mind skills are related to gray matter volume in the ventromedial prefrontal cortex in schizophrenia

Disease Modification in Schizophrenia: Overview of the Issues. ISCTM February 18 th 2014 Ravi Anand, MD Switzerland

Supplementary Results: Age Differences in Participants Matched on Performance

Neuroimaging for Diagnosis of Psychiatric Disorders

Overt vs. Covert Responding. Prior to conduct of the fmri experiment, a separate

Experimental Medicine and Psychiatry Drug Development. John H. Krystal, M.D. Yale University

Neuroimaging and Psychiatry

FUNCTIONAL MRI CORRELATES OF SCHIZOPHRENIA NEGATIVE SYMPTOMS DURING AUDITORY ODDBALL TASK AND RESTING STATE. Joseph James Shaffer Jr.

Pro-cognitive strategies in Bipolar Disorder: Challenges and New Directions. Sophia Frangou, MD, PhD, FRCPsych Professor of Psychiatry

Stuttering Research. Vincent Gracco, PhD Haskins Laboratories

Clinical predictors of therapeutic response to antipsychotics in schizophrenia

BINGES, BLUNTS AND BRAIN DEVELOPMENT

WFOT congress in 2018 Association between employment outcomes and symptomatic remission in chronic patients with schizophrenia

Visual Context Dan O Shea Prof. Fei Fei Li, COS 598B

A SYSTEMATIC REVIEW OF STRUCTURAL AND FUNCTIONAL MRI DIFFERENCES BETWEEN PSYCHOTIC AND NONPSYCHOTIC DEPRESSION

Supplemental information online for

Differential contributions of subregions of medial temporal lobe to memory system in. amnestic mild cognitive impairment: insights from fmri study

Schizophrenia as a disorder of thought, or language? Evidence from brain and behavioral investigations

SUPPLEMENTARY MATERIAL. Table. Neuroimaging studies on the premonitory urge and sensory function in patients with Tourette syndrome.

Supplementary Material. Functional connectivity in multiple cortical networks is associated with performance. across cognitive domains in older adults

Henry Molaison. Biography. From Wikipedia, the free encyclopedia

MICHAEL A. YASSA, M.A. Curriculum Vitae 11/24/08

Identifying Youth at Clinical High Risk for Psychosis

POT WEED CHRONIC GREEN KUSH BUD HERB

Resistance to forgetting associated with hippocampus-mediated. reactivation during new learning

Neuroplasticity: functional MRI techniques M.A. Rocca

Supplementary materials. Appendix A;

Voxel-based morphometry in clinical neurosciences

Neuroimaging in the Field of Psychoses

HST.583 Functional Magnetic Resonance Imaging: Data Acquisition and Analysis Fall 2006

Diffusion Tensor Imaging in Psychiatry

Suboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies

Brief Report. Resilience, Recovery Style, and Stress in Early Psychosis

Age-related cortical thickness trajectories in first episode psychosis patients presenting with early persistent negative symptoms

Psychopathology in patients with schizophrenia attending a psychiatry outpatient clinic at a tertiary care hospital

Neural activity to positive expressions predicts daily experience of schizophrenia-spectrum symptoms in adults with high social anhedonia

10 years of CBT at PEPP-Montréal: A service level perspective

Brain Imaging Applied to Memory & Learning

Childhood maltreatment, latent vulnerability and the shift to preventative help:

Virtual Reality Testing of Multi-Modal Integration in Schizophrenic Patients

Supplementary appendix

Outcomes in Schizophrenia Systematic Reviews

Cover Page. The handle holds various files of this Leiden University dissertation

Resting-State functional Connectivity MRI (fcmri) NeuroImaging

Thalamocortical Synchronization and Cognition: Implications for Schizophrenia?

Details of Atypical Antipsychotic Drugs for Schizophrenia Patients. Resting-State Functional MR Imaging Data Acquisition and

Two cortical systems for memoryguided

Supplementary Online Content

APPLICATIONS OF ASL IN NEUROSCIENCE

Diffusion Tensor Imaging in Dementia. Howard Rosen UCSF Department of Neurology Memory and Aging Center

Cognitive Neuroscience of Memory

Bizarre delusions and DSM-IV schizophrenia

Decision neuroscience seeks neural models for how we identify, evaluate and choose

Right lateral prefrontal cortex Specificity for inhibition or strategy use?

Reviews and Overviews. Mechanisms of Psychiatric Illness

Neural correlates of recognition memory of social information in people with schizophrenia

A possible mechanism for impaired joint attention in autism

Neuroimaging Findings in Young Drinkers: Does Teenage Drinking Harm the Brain? Susan F. Tapert, Ph.D. University of California, San Diego

NeuRA Frontal lobe March 2017

Schizophrenia: New Concepts for Therapeutic Discovery

There are, in total, four free parameters. The learning rate a controls how sharply the model

Presenter Disclosure Information

Relationship Between Duration of Untreated Psychosis and Outcome in First-Episode Schizophrenia: A Critical Review and Meta-Analysis

Long-term associations between use of antipsychotic medication and brain structural changes in schizophrenia

EVALUATION OF WORRY IN PATIENTS WITH SCHIZOPHRENIA AND PERSECUTORY DELUSION COMPARED WITH GENERAL POPULATION

The two sides of human thought. Human thinking: Lessons from Neuroscience. Patient studies. Kalina Christoff Vancouver, BC May 29, 2007

Supplementary Online Content

Insight in Mental Illness:

Gray matter networks and cognitive impairment in multiple sclerosis

Neuroimaging biomarkers and predictors of motor recovery: implications for PTs

Est-ce que l'eeg a toujours sa place en 2019?

Biomedical Research 2018; 29 (1): ISSN X

Stimulus content and the neural correlates of source memory

Supplementary Online Content

Curriculum Vitae B.A. in Neuroscience (General and Departmental Honors) Johns Hopkins University School of Arts and Sciences, Baltimore MD

Psychosis. Paula Gibbs, MD Department of Psychiatry University of Utah

When & How to Use ECT in Older Adults. Frans Hugo SJOG Midland Hospital, PERTH

Chapter 3. Klinefelter's syndrome (karyotype 47,XXY) and schizophrenia-spectrum pathology. Sophie van Rijn, André Aleman, Hanna Swaab, René S Kahn

Bipolar disorder risk gene FOXO6 modulates negative symptoms in schizophrenia: a neuroimaging genetics study

Funding: NIDCF UL1 DE019583, NIA RL1 AG032119, NINDS RL1 NS062412, NIDA TL1 DA

NIH Public Access Author Manuscript Am J Psychiatry. Author manuscript; available in PMC 2009 October 26.

Characteristics of trees drawn by patients with paranoid schizophrenia

Bertha K Madras, PhD Professor of Psychobiology Department of Psychiatry Harvard Medical School McLean Hospital

Supporting online material for: Predicting Persuasion-Induced Behavior Change from the Brain

Transcription:

Early identification of neurobiological markers of remission Michael Bodnar, PhD Ashok K. Malla, MD Martin Lepage, PhD

Outline Why study remission? Defining remission Data collection Results neurocognition neuroimaging: smri & fmri Conclusions & Future Direction

Why study remission? heterogeneity of outcome (Emsley et al, 2011, Curr Opin Psychiatry) inability to predict response early on (Menezes et al, 2006, Psychol Med) trial-and-error treatment strategy ongoing assessments careful monitoring of response and side-effects (Tandon et al, 2010, Schizophr Res) the challenge: to better understand the heterogeneity of outcome following a first-episode of psychosis identify markers of remission

Remission in schizophrenia PANSS level : mild or less 1 Absent 2 Minimal 3 Mild 4 Moderate 5 Moderately Severe 6 Severe 7 Extreme on all 8 core symptoms delusions hallucinatory behavior unusual thought content blunted affect passive or apathetic social withdrawal lack of spontaneity & flow of conversation mannerisms & posturing conceptual disorganization sustained for at least 6 months (Andreasen et al, 2005, Am J Psychiatry)

Data Collection Symptom evaluations Month 6 Month 12 Month 24 Neurocognition Neuroimaging structural MRI functional MRI DTI Neurocognition Neuroimaging structural MRI Since 2003 500+ clients treated Since 2004 smri: 135 initial, 68 fup1, & 47 fup2 Neuroimaging structural MRI DTI

Remission Rates Early Remission Month 6 Month 12 Remitted Non-Remitted FES sample Neuroimaging Neurocognition n=39, 20% n=16, 23% n=25, 23% n=157, 80% N=55, 77% n=83, 77% Percentages in line with other studies (Emsley et al, 2011, Curr Opin Psychiatry) rates varied from 19% to 88%

Neurocognition 0,0 z score -0,5-1,0 p=0.006-1,5-2,0 Verbal Memory Visual Memory Working Memory Speed of Processing (adapted from Bodnar et al, 2008, Br J Psychiatry) Reasoning/Problem Solving Non-Remitted (n=83) Remitted (n=25) Control (n=49) FES (n=108) Attention MATRICS Measurement and Treatment Research to Improve Cognition in Schizophrenia (Nuechterlein et al, 2004, Schizophr Res)

Automated whole-brain analysis (VBM8) right parahippocampal gyrus left hippocampus Areas with lower grey matter in non-remitted (n=41) compared to remitted (n=17) (p<0.001, uncorrected) (adapted from Bodnar et al, 2011, Clin Schizophr Related Psychoses)

Parahippocampus & Hippocampus Parahippocampal Entorhinal Perirhinal Tail Head Body Amygdala (Pruessner et al, 2002, Cereb Cortex) (Pruessner et al, 2000, Cereb Cortex) (Bodnar et al, 2010, Schizophr Res)

Verifying the VBM results... 3000 Parahippocampal Cortex 900 Hippocampus Tail 2800 800 2600 700 2400 600 2200 p=0.031 Left p=0.005 Right 500 p=0.001 Left p=0.027 Right (adapted from Bodnar et al, 2012, Psychiatry Res) Correlation, No significant Right differences Side in Social Withdrawal: -0.351, p=0.008 entorhinal or perirhinal cortices. Verbal Memory: 0.349, p=0.009 (adapted from Bodnar et al, 2010, Schizophr Res) No There significant were no differences significant in body or or head trend-level subregions correlations. amygdala. Non-Remitted (n=41) Remitted (n=17)

fmri Behavioral Task + + Which Alive or one not is bigger? alive? Encoding Strategy Semantic Relatedness 2x2 design Related Unrelated Associative Associativerelated Associativeunrelated (Achim et al, 2007, JAMA Psychiatry) Item-Oriented Item-related Item-unrelated

Related > Unrelated: Non-Remitted > Remitted 2.00 Posterior cingulate in schizophrenia: 1.50 remains overactive when mentally engaged 1.00 0.00-0.50 1.49-1.00-1.35 memory (Broyd et al, 2009, Neurosci Biobehav Rev; Mannell et al, 2010, Hum Brain Mapp) -1.50 Non-Remitted Remitted (Bodnar et al, 2012, Br J Psychiatry) left posterior cingulate peak voxel: x=-10, y=-57, z=12 cluster size: 130 voxels; t-value: 4.91 (Garrity et al, 2007, Am J Psychiatry; Meda et al, 2009, PLoS One; Whitfield-Gabrieli et al, 2009, Proc Natl Acad Sci USA) 0.50 hyper-activity worse memory (Meda et al, 2009, PLoS One; Whitfield-Gabrieli et al, 2009, Proc Natl Acad Sci USA) No significant differences for: associative > item-oriented or successful > unsuccessful PCC fails to turn off leading to over-sampling and unfocused attention poorer

Summary of results Non-Remitted: poorer verbal memory smaller hippocampus tail & parahippocampal cortex abnormal activity in posterior cingulate Posterior memory-related neural network differences between remitted & non-remitted FES patients Markers identified may be related to either positive or negative symptoms or both

Conclusions & Future Directions A better understanding of clinical outcome and of schizophrenia Highlight specific areas for future clinical research developing newer, target-specific treatments Negative (and positive) symptoms should be explored in further detail to determine specificity of markers related to remission

Thank you All personnel at PEPP Dr. Srividya Iyer Dr. Ridha Joober Dr. Ashok Malla All current and former lab members Hazel Sutton Audrey Benoit Jennifer Dell Elce Dr. Amelie Achim Dr. Philippe-Olivier Harvey Dr. Martin Lepage All of the clients and especially those who have kindly given their time to take part in our research.

Symptomatic profiles Positive Symptom Total Negative Symptom Total 35 30 25 20 15 * * * 35 30 25 20 15 * * * * * 10 10 5 5 0 First Assessment Month 3 Month 6 Month 9 Month 12 0 First Assessment Month 3 Month 6 Month 9 Month 12 * p<0.01 * p<0.001 Non-Remitted (n=83) Remitted (n=25)

Negative symptoms in remission Non-Remitted n=83, 77% n=33 Psychoticism Negative n=16 n=2 n=32 Disorganization Mixed Correlation: Parahippocampal Cortex and Social Withdrawal Right, -0.351, p=0.008 Left, -0.297, p=0.026 Individual symptoms for not achieving remission: 1 delusions; 3 hallucinations 2 conceptual disorganization 7 blunted affect; 12 social withdrawal; 2 lack of spontaneity

Remitted vs. Non-Remitted 1 year 2 year Non-Remitted n=157, 80% Remitted N=39, 20% Non-Remitted Remitted n=113, 72% N=53, 32% R NR: 9 NR R: 14

Cortical Thickness right Medial left parahippocampal gyrus posterior cingulate Red = areas with less thickness in non-remitted (p<0.01, corrected) 56 FES: 39 non-remitted & 17 remitted

Parahippocampal Gyrus mm 3 3500 3000 Non-Remitted (n=41) Remitted (n=17) Controls (n=5) 2500 2000 1500 1000 p=0.031 Parahippocampal Perirhinal Entorhinal Parahippocampal Perirhinal Entorhinal Left p=0.005 Right Comparison between non-remitted and remitted patients only. No significant [group x region x side] interaction: F=0.36, df=2,54, p=0.70

Hippocampus Tail

Parahippocampal Cortex mm 3 Non-Remitted (n=41) Remitted (n=17) 3000 * Correlation: 2800 Social Withdrawal Right, -0.351, p=0.008 Left, -0.297, p=0.026 2600 2400 2200 p=0.031 Left p=0.005 Right No significant differences in entorhinal or perirhinal cortices (adapted from Bodnar et al, 2012, Psychiatry Res)

Hippocampus Tail mm 3 900 800 Non-Remitted (n=41) * Remitted (n=17) No significant correlations 700 600 500 p=0.001 Left p=0.027 Right No significant differences in body or head subregions or amygdala (adapted from Bodnar et al, 2010, Schizophr Res)

Hippocampus Tail 1 year follow-up 900 850 800 p=0.009 p=0.163 p=0.137 p=0.006 750 700 650 First Assessment Follow-Up Left Right Non-Remitted (n=26) Remitted (n=12)

DTI: posterior cingulum bundle 0.400 Non-Remitted (n=14) Remitted (n=9) 0.380 FA Value 0.360 0.340 0.359 0.360 0.351 0.349 0.320 Right Posterior Cingulum Left Posterior Cingulum posterior cingulum bundle: hippocampus to cingulate

Defining remission Consensus definition of remission in schizophrenia published in 2005 (Andreasen et al, Am J Psychiatry, 2005, 162:441-449). Measured with PANSS, SAPS & SANS, or BPRS & SANS. Easily implemented in clinical trials and clinical practice. Can easily and directly compare studies of outcome and across cultures. (van OS et al, Acta Psychiatr Scand, 2006, 113:91-95).

Defining remission Negative symptoms equally important: higher baseline levels related to a poorer outcome (White et al, Psychol Med, 2009, 39: 1447-1456) necessary to properly assess remission (Cassidy et al, Schizophr Bull, 2010, 36: 1001-1008). 6-month time component as symptoms tend to fluctuate 3-month equally valid (Cassidy et al, Schizophr Bull, 2010, 36: 1001-1008). (Moller, Eur Psychiatry, 2007, 22:380-386)